TBP301

TBP301 is an investigational allogeneic cell therapy candidate developed by FibroGenesis (a subsidiary of SpinalCyte) for the treatment of chronic pain and opioid addiction. The therapy utilizes human dermal fibroblasts (HDFs), which are hypothesized to modulate biological and neurological pathways involved in pain signaling and addictive behaviors. While the specific molecular targets are not publicly disclosed, the platform leverages the regenerative and immunomodulatory properties of fibroblasts to address the underlying pathology of pain and the neurological components of addiction. TBP301 is currently in the preclinical stage of development.